CompletedNot Applicable

Caffeine vs. ALA in BMS Treatment. (BMS: Burning Mouth Syndrome. ALA: Alpha-Lipoic Acid.)

China130 participantsStarted 2021-12-13

Plain-language summary

The aim of this study was to evaluate the efficacy of caffeine and alpha-lipoic acid in the treatment of burning mouth syndrome by symptom assessment with visual analogue scale.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Secondary BMS due to local or systemic disorders
✕. Prior treatment for BMS
✕. Psychiatric or progressive neurological disorders
✕. Systemic disorders potentially associated with oral disease
✕. Long-term history of smoking, drinking, or medication use
✕. Consumption of caffeinated products
✕. Poor oral hygiene
✕. Abnormal blood test results (including blood count, glucose, serum iron, ferritin and transferrin, folic acid, or vitamin B12 levels)

What they're measuring

Visual Analogue Scale (VAS)

Timeframe: Baseline and 2 weeks after intervention or observation

Trial details

NCT IDNCT06195137

SponsorLu Jiang

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-06-15

View on ClinicalTrials.gov More Caffeine trials